US FDA grants pediatric exclusivity for UCB's Keppra(R)
* Period of exclusivity until January 2009 in the US
* Pediatric indication filed with FDA
BRUSSELS, BELGIUM--Jun 6, 2008 -- Brussels, BELGIUM - June 6, 2008 at 7:00 am CEST - UCB announced today that the US Food and Drug Administration (FDA) has gra... Biopharmaceuticals, FDAUCB, Keppra, levetiracetam, '639 patent (Source: HSMN NewsFeed)
Table of Contents
Typical and Atypical Antipsychotics Both Linked to Increased Risk of StrokeStudy Shows SSRIs Most Strongly Linked to Osteoporotic FracturesHyperammonemic Encephalopathy Associated With ValproateLow Vitamin B12 Levels Linked to Loss of Brain Volume in the ElderlyQuetiapine for Bipolar Mania in Older AdultsDiscontinuing Antipsychotics in Dementia PatientsPrebagalin as a Potential Treatment for Lithium-Induced TremorFDA Approval of Phase II Trial for SerdaxinNew Approval of Levetiracetam (Keppra XR) Extended-Release TabletsFDA Requesting Additional Data for Injectable Paliperidone (Source: The Brown University Geriatric Psychopharmacology Update)div id=medwormpbiMedWorm Message:/i/b Please support the a href=http://www.doctorsinchains.org/ target=_blankDoctors In Chains/a campaign for the a href=http://www.doctorsinchains.org/medics/a tortured and sentenced for up to 15 years in a href=http://www.doctorsinchains.org/Bahrain/a. a href=https://twitter.com/#!/search/%23FreeDoctors#FreeDoctors/a/p/div
